Antibiofilm approaches as a new paradigm for treating infections

Fany Reffuveille, Yasser Dghoughi, Marius Colin, Marcelo D. T. Torres, César de la Fuente‐NúñezProgress 2024 · DOI

TL;DR

The rise of antibiotic resistance is a critical global health threat, largely driven by bacteria forming resilient biofilms. This paper reviews current and emerging strategies to combat these biofilms, highlighting the growing importance of computational approaches, particularly AI, in accelerating the discovery of novel antibiofilm agents.

What Problem Does This Paper Address?

Antibiotic resistance is a major public health crisis, and a significant portion of bacterial infections are caused by biofilms. Biofilms are structured communities of bacteria encased in a protective matrix, making them far more resistant to antibiotics than free-floating (planktonic) bacteria. Current antibiotics are primarily designed to target planktonic bacteria, leaving biofilm infections largely untreatable by conventional means. This gap in treatment options necessitates the development of new strategies specifically targeting biofilms.

Methods

The paper provides a comprehensive review of various antibiofilm approaches, categorizing them into:

  • Antibiotics: Discusses existing antibiotics that show antibiofilm activity, focusing on their mechanisms of action against cell wall synthesis, cytoplasmic targets, and outer membranes. It also explores combinations of antibiotics and the challenges of resistance.
  • New Therapies: Reviews emerging treatments like bacteriophage cocktails, probiotics, and antimicrobial peptides (AMPs). AMPs are highlighted for their broad-spectrum activity, low concentrations required, and potential for synergistic effects with antibiotics.
  • Biofilm Models: Examines different laboratory models used to study biofilms and test antibiofilm agents. This includes static models like the Biofilm Ring Test (BRT) and the Calgary Biofilm Device (CBD), as well as dynamic models like flow cells. The limitations of current models in fully replicating the in vivo environment are discussed.
  • Engineering Approaches: Covers strategies that modify surfaces to prevent biofilm formation or kill bacteria, such as functionalizing surfaces with polymer brushes or creating textured surfaces.
  • Computational Approaches: Details the increasing role of computational methods, including molecular docking, molecular dynamics, quantitative structure-activity relationship (QSAR) modeling, and machine learning (ML). These methods are crucial for predicting compound efficacy, designing new molecules, and accelerating the discovery process.

Datasets

Not explicitly detailed as distinct datasets for training or evaluation in the context of a machine learning model. However, the paper references the use of various databases for virtual screening, such as the Food and Drug Administration (FDA)-approved list and natural product databases. The development of ML models like Molib and TargIDe relies on curated datasets of known antibiofilm and non-inhibitory molecules.

Key Insights and Ideas

  • Biofilms are the primary culprit: The vast majority of bacterial infections involve biofilms, yet dedicated antibiofilm therapies are scarce.
  • Conventional antibiotics fall short: Existing drugs are ill-equipped to tackle the robust defenses of biofilms.
  • New therapeutic avenues are promising: Bacteriophages, probiotics, and especially AMPs offer exciting alternatives with unique mechanisms.
  • Lab models need improvement: Current in vitro models often fail to capture the complexity of in vivo biofilm environments, contributing to the limited success of some promising compounds.
  • AI is a game-changer for drug discovery: Machine learning and other computational tools are revolutionizing the speed and efficiency of identifying and designing novel antibiofilm agents.
  • Synergy is key: Combining different approaches (e.g., antibiotics with AMPs, or computational design with experimental validation) is crucial for overcoming resistance and achieving effective eradication.

Key Results

The paper doesn't present novel experimental results but rather synthesizes findings from numerous studies. Key takeaways from the reviewed literature include:

  • Certain cephalosporins (ceftarolin, ceftopibrole) and lipoglycopeptides (dalbavancin) show promising in vitro antibiofilm activity against specific bacteria.
  • Synthetic AMPs have demonstrated excellent broad-spectrum antibiofilm activity at low concentrations.
  • Machine learning models have shown high accuracy (e.g., >0.90) in predicting antibiofilm activity based on molecular features.
  • ML-based virtual screening approaches have significantly increased hit rates for identifying potential antibiofilm compounds compared to traditional methods.
  • Computational methods, when combined, can accelerate the identification of promising antibiofilm candidates with specific mechanisms of action.

Limitations and Future Work

Limitations:

  • In vitro vs. In vivo Discrepancy: Many compounds effective in lab settings show limited efficacy in real-world infections, often due to the complex in vivo environment.
  • Model Limitations: Current biofilm models may not fully recapitulate the physiological context of infections, leading to a gap in predictive power.
  • Resistance Development: Bacteria in biofilms can develop resistance to even novel antibiofilm agents.
  • Computational Cost: While powerful, some computational methods like molecular dynamics can be computationally expensive.

Future Work:

  • Development of more sophisticated biofilm models: Creating models that better mimic the in vivo environment is crucial for accurate screening.
  • Accelerated discovery through AI: Continued integration of AI and machine learning with experimental validation is expected to rapidly advance the discovery of new antibiofilm molecules.
  • Exploring synergistic combinations: Further research into combining different therapeutic modalities (e.g., AMPs with antibiotics, or engineering approaches with drugs) will be vital.
  • Targeting specific biofilm components: Developing agents that specifically disrupt biofilm structure or function, rather than just killing bacteria, holds significant promise.
  • Translational research: Bridging the gap between promising in vitro findings and successful clinical applications remains a key challenge.

Summary updated

Abstract

The lack of effective antibiotics for drug-resistant infections has led the World Health Organization to declare antibiotic resistance a global priority. Most bacterial infections are caused by microbes growing in structured communities called biofilms. Bacteria growing in biofilms are less susceptible to antibiotics than their planktonic counterparts. Despite their significant clinical implications, bacterial biofilms have not received the attention they warrant, with no approved antibiotics specifically designed for their eradication. In this paper, we aim to shed light on recent advancements in antibiofilm strategies that offer compelling alternatives to traditional antibiotics. Additionally, we will briefly explore the potential synergy between computational approaches, including the emerging field of artificial intelligence, and the accelerated design and discovery of novel antibiofilm molecules in the years ahead.
BibTeX
@inproceedings{reffuveille2024antibiofilm,
  author = {Fany Reffuveille and Yasser Dghoughi and Marius Colin and Marcelo D. T. Torres and César de la Fuente‐Núñez},
  title = {{Antibiofilm approaches as a new paradigm for treating infections}},
  booktitle = {Progress},
  year = {2024},
  doi = {10.1088/2516-1091/ad1cd6},
}
Figure